Stonepine Capital Management LLC Makes New $1.66 Million Investment in CalciMedica, Inc. (NASDAQ:CALC)

Stonepine Capital Management LLC bought a new position in shares of CalciMedica, Inc. (NASDAQ:CALC) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 468,793 shares of the company’s stock, valued at approximately $1,660,000. CalciMedica comprises approximately 1.3% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 22nd largest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cetera Investment Advisers lifted its stake in CalciMedica by 37.1% during the fourth quarter. Cetera Investment Advisers now owns 16,873 shares of the company’s stock worth $60,000 after purchasing an additional 4,566 shares during the last quarter. Atria Investments Inc lifted its stake in CalciMedica by 28.3% during the fourth quarter. Atria Investments Inc now owns 34,012 shares of the company’s stock worth $120,000 after purchasing an additional 7,509 shares during the last quarter. Corient Private Wealth LLC bought a new stake in CalciMedica during the fourth quarter worth $135,000. Renaissance Technologies LLC bought a new stake in CalciMedica during the fourth quarter worth $153,000. Finally, Millennium Management LLC lifted its stake in CalciMedica by 30.5% during the fourth quarter. Millennium Management LLC now owns 72,057 shares of the company’s stock worth $255,000 after purchasing an additional 16,824 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of CalciMedica in a research note on Thursday.

CalciMedica Stock Performance

Shares of NASDAQ:CALC opened at $2.00 on Friday. The company has a fifty day moving average of $1.80 and a 200-day moving average of $2.53. The company has a market capitalization of $27.94 million, a PE ratio of -1.85 and a beta of 1.24. CalciMedica, Inc. has a 52-week low of $1.43 and a 52-week high of $6.02.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. On average, equities analysts forecast that CalciMedica, Inc. will post -2.21 EPS for the current fiscal year.

CalciMedica Company Profile

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.